Dapagliflozin use in tolvaptan-treated patients with ADPKD: exploring renal outcomes in a retrospective study
Although no statistically significant differences were observed, both between- and within-group analyses showed a numerically slower decline in eGFR with dapagliflozin. Importantly, no evidence of harm was observed. These findings may contribute to ongoing discussions regarding the potential role of SGLT2i in ADPKD.
Authors
- Shun Minatoguchi (ORCID: https://orcid.org/0000-0002-5203-2974)
- Shigehisa Koide
- Naotake Tsuboi (ORCID: https://orcid.org/0000-0003-0760-845X)
- Ryosuke Umeda (ORCID: https://orcid.org/0000-0002-4607-2136)
- Midori Hasegawa (ORCID: https://orcid.org/0000-0001-8820-9682)
- Hiroki Hayashi (ORCID: https://orcid.org/0000-0001-5397-3904)
- Ryuichi Nakajima (ORCID: https://orcid.org/0000-0002-0024-4422)
Institutions
- Fujita Health University (JP)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1093/ckj/sfaf269
- Primary Topic
- Biomedical Research and Pathophysiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00